Latest Insider Transactions at Prelude Therapeutics Inc (PRLD)
This section provides a real-time view of insider transactions for Prelude Therapeutics Inc (PRLD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Prelude Therapeutics Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Prelude Therapeutics Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 16
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
28,751
-72.25%
|
$460,016
$16.15 P/Share
|
|
Nov 16
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
28,751
+49.62%
|
$345,012
$12.85 P/Share
|
|
Oct 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-75.07%
|
$465,000
$31.21 P/Share
|
|
Oct 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Sep 07
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-62.72%
|
$540,000
$36.87 P/Share
|
|
Sep 07
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Sep 02
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
17,000
-39.88%
|
$697,000
$41.44 P/Share
|
|
Sep 02
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+45.03%
|
$204,000
$12.85 P/Share
|
|
Aug 27
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,014
-1.13%
|
$216,504
$36.21 P/Share
|
|
Aug 27
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,014
+3.25%
|
$6,014
$1.43 P/Share
|
|
Aug 26
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,700
-0.97%
|
$59,500
$35.19 P/Share
|
|
Aug 26
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+0.96%
|
$1,700
$1.43 P/Share
|
|
Aug 25
2021
|
Brian Piper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,333
-62.53%
|
$274,989
$33.33 P/Share
|
|
Aug 25
2021
|
Brian Piper Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+50.0%
|
$8,333
$1.89 P/Share
|
|
Aug 13
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,286
-1.3%
|
$80,010
$35.07 P/Share
|
|
Aug 13
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,286
+0.65%
|
$2,286
$1.66 P/Share
|
|
Aug 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-65.63%
|
$465,000
$31.44 P/Share
|
|
Aug 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Jul 27
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-5.2%
|
$700,000
$35.77 P/Share
|
|
Jul 27
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.39%
|
$20,000
$1.43 P/Share
|
|
Jul 06
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-87.68%
|
$420,000
$28.05 P/Share
|
|
Jul 06
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Jun 07
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-38.65%
|
$465,000
$31.57 P/Share
|
|
Jun 07
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
May 25
2021
|
Brian Piper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,333
-69.44%
|
$283,322
$34.79 P/Share
|
|
May 25
2021
|
Brian Piper Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+50.0%
|
$8,333
$1.89 P/Share
|
|
May 07
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.85%
|
$410,000
$41.1 P/Share
|
|
May 07
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.18%
|
$10,000
$1.43 P/Share
|
|
May 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-71.06%
|
$600,000
$40.24 P/Share
|
|
May 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Apr 29
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
3,223
-87.89%
|
$128,920
$40.29 P/Share
|
|
Apr 29
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
3,223
+46.78%
|
$3,223
$1.89 P/Share
|
|
Apr 29
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
3,295
-46.77%
|
$131,800
$40.29 P/Share
|
|
Apr 29
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Exercise of conversion of derivative security
|
Direct |
3,295
+31.87%
|
$3,295
$1.89 P/Share
|
|
Apr 27
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-73.62%
|
$875,000
$35.48 P/Share
|
|
Apr 27
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$25,000
$1.89 P/Share
|
|
Apr 19
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.0%
|
$775,000
$31.05 P/Share
|
|
Apr 19
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$25,000
$1.89 P/Share
|
|
Apr 08
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,617
-46.1%
|
$365,446
$38.36 P/Share
|
|
Apr 08
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,617
+50.0%
|
$9,617
$1.89 P/Share
|
|
Apr 08
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
100
-18.38%
|
$4,000
$40.0 P/Share
|
|
Apr 08
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+15.53%
|
$100
$1.89 P/Share
|
|
Apr 08
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
200
-5.06%
|
$8,000
$40.0 P/Share
|
|
Apr 08
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Grant, award, or other acquisition
|
Direct |
200
+4.82%
|
$200
$1.89 P/Share
|
|
Apr 08
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,630
-0.66%
|
$175,940
$38.31 P/Share
|
|
Apr 08
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,630
+2.54%
|
$4,630
$1.43 P/Share
|
|
Apr 07
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,383
-76.98%
|
$599,937
$39.36 P/Share
|
|
Apr 07
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,383
+50.0%
|
$15,383
$1.89 P/Share
|
|
Apr 07
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
1,000
-69.25%
|
$40,000
$40.04 P/Share
|
|
Apr 07
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+40.92%
|
$1,000
$1.89 P/Share
|